Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Robert Lavender

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
DivisionInternal Med General Medicine
Address7D 14 Central Building (old hospital)
4301 W.Markham
Mail Slot # 641
Little Rock AR 72205
Phone501-686-5236
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    ACT 12374     (LAVENDER, ROBERT C)Mar 22, 2012
    Sanofi Pasteur, Inc.
    A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin gargine/lixisenatide fixed rat
    Role: Principal Investigator
    ACT12374     (LAVENDER, ROBERT C)Mar 22, 2012
    Sanofi Pasteur, Inc.
    A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin gargine/lixisenatide fixed rat
    Role: Principal Investigator
    EFC11319     (LAVENDER, ROBERT C)Sep 12, 2011
    Sanofi-Aventis
    A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenati
    Role: Principal Investigator
    DU     (LAVENDER, ROBERT)Apr 19, 2011
    Daiichi Pharmaceutical Corporation
    A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LM
    Role: Principal Investigator
    DU-176B     (LAVENDER, ROBERT C)Apr 19, 2011
    Daiichi Pharmaceutical Corporation
    A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LM
    Role: Principal Investigator
    BMS     (LAVENDER, ROBERT)Dec 3, 2009
    Pfizer, Inc.
    A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN IN THE TREATMENT OF SYMPTOMATIC DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM”
    Role: Principal Investigator
    BMS-562247     (LAVENDER, ROBERT C)Dec 3, 2009
    Pfizer, Inc.
    A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN IN THE TREATMENT OF SYMPTOMATIC DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM”
    Role: Principal Investigator
    BIBR 1048     (LAVENDER, ROBERT C)Jul 24, 2009
    Boehringer Ingleheim Pharmaceuticals, Inc.
    A Phase III Randomized, double blind, parallel-group stuyd of the efficacy and safety of oral dabigatran etexilate (150 mg bid)compared to warffarin (
    Role: Principal Investigator
    BIBR1048     (LAVENDER, ROBERT C)Jul 24, 2009
    Boehringer Ingleheim Pharmaceuticals, Inc.
    A Phase III Randomized, double blind, parallel-group stuyd of the efficacy and safety of oral dabigatran etexilate (150 mg bid)compared to warffarin (
    Role: Principal Investigator
    11702     (LAVENDER, ROBERT C)Jul 6, 2009
    Bayer Corporation (Bayer USA)
    Protocol #11702 entitled: “Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis and/or pulmonary emboli
    Role: Principal Investigator
    XRP4563C/3501     (LAVENDER, ROBERT C)Mar 31, 2003 - Dec 31, 2003
    Aventis Pharmaceuticals, Inc.
    A double-blind, placebo-controlled, parallel, multicenter study on extended VTE prophylaxix in acutely ill medical patients with prolonged immobilizat
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Kaatz S, Mahan CE, Nakhle A, Gunasekaran K, Ali M, Lavender R, Paje DG. Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants. Curr Cardiol Rep. 2017 10 24; 19(12):124. PMID: 29064044.
      View in: PubMed
    2. Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG. Reversing factor Xa inhibitors - clinical utility of andexanet alfa. J Blood Med. 2017; 8:141-149. PMID: 28979172.
      View in: PubMed
    3. Dholaria BR, Pant S, Lavender RC, Agarwal A. The great imitator: psychosis that responded to penicillin. Can Fam Physician. 2014 Sep; 60(9):818-21. PMID: 25217678.
      View in: PubMed
    4. Achanta L, Bhaskar N, Lavender R. Perioperative risk assessment. J Ark Med Soc. 2014 Jun; 110(13):278-9. PMID: 25004668.
      View in: PubMed
    5. Kaatz S, Qureshi W, Lavender RC. Venous thromboembolism: what to do after anticoagulation is started. Cleve Clin J Med. 2011 Sep; 78(9):609-18. PMID: 21885694.
      View in: PubMed
    6. Lavender R, Kaatz S, Qureshi W. Venous thromboembolic disease: what to do after anticoagulation is started. Cleveland Clinic Journal of Medicine. 2011; 78:609-618.
    7. Golden WE, Lavender RC. Preventing perioperative venous thromboembolism: Risk asesment, prevention could save lives. Jpurnal of the Arkansas Medical Society. 2006.
    8. Golden WE, Lavender R. Venous thromboembolism: risk assessment, prevention could save lives. J Ark Med Soc. 2006 Aug; 103(2):32-3. PMID: 16910224.
      View in: PubMed
    9. Goldhaber SZ, Tapson VF, Elkayam U, Bosker G, Lavender RC. Phrophylaxis of Venous Thromboembolism (VTE) in The Hospitalized Patient. The DVT Medical Prophylaxis Concensus Panel Report. Hospital Medicine Consensus Reports. 2003.
    10. Lavender RC, Sung J, Nix L. Eficacy of enoxaparin versus warfarin in DVT prevention as asesed by duplex scaning in post hip and kne arthroplasty patients. Suplement to the Journal Thrombosis and ahaemostasis. 2001.
    11. Hull RD, Pineo GF, Francis C, Lavender RC(co-author). Low-molecular weight heparin prophylaxis using dalteparin extended out-of-hospital vs. in-hospital warfarin/ out-of0hospital placebo in hip arthroplasty patients. Archives of Internal Medicine. 2000; 160:2208-2215.
    12. Hull RD, Pineo GF, Francis C, Lavender RC(co-arthur). Low-molecular weight heparin prophylaxis using dalteparin in close proximity to surgery vs. warfarin in hip arthroplasty patients. Archives of Internal Medicine. 2000; 160:2199-2207.
    13. Lavender RC. Clinical pathways for DVT prevention and management in alternative care sites. Home Health Care Consultant Suplement. 1999.
    14. Mohr DN, Lavender RC. Preoperative pulmonary evaluation. Poetgraduate Medicine. 1996; 100:241-256.
    15. Sparling EA, Nelson CL, Lavender RC, Smith J. The use of erythrpoietin in the management of Jehovah's Witneses who have revision total hip arthroplasty. Journal of Bone and Joint Surgery. 1996; 78:1548-1552.
    16. Abraham S, Fleisher LA, Lavender RC, Tape TG. The pre-op evaluation. How much is enough?. Patient Care. 1993; 27:149-171.
    17. Gloden WE, Lavender RC. Perioperative medical considerations in Ferlito A. 1993.
    18. Barnes CL, Nix ML, Lavender RC, Nelson CL. Duplex screning in orthopedic patients. Contemporary Orthopaedics. 1991; 22:283-286.
    19. Barnes CL, Nelson CL, McCowan TC, Lavender RC, Barnes RW. Duplez scaning versus venography as a screning examination in total hip arthroplasty patients. Clinical Orthopaedics and Related Research. 1991; 271:180-189.
    20. Lavender RC. Low molecular weight heparin 115:231-232. 1991.
    21. Nelson CL, Barnes CL, Lavender RL, Golden WE, Harmon BH, Ferris EJ, Barnes RW. Fate of calf vein thrombosis in patients undergoing total joint replacement. The American Venous Forum. 1989.
    22. Golden WE, Lavender RC. The medical care of the ENT patient in Meyers EN and Suen JY. 1989.
    23. Golden WE, Lavender RC, Metzer WS. Acute postoperative confusion and halucinations in Parkinson's disease. Anals of Internal Medicine. 1989; 111:218-222.
    24. Lavender RC, Barnes CS, Golden WE. Dihydroergotamine/ Heparin. The Journal of Bone and Joint Surgery. 1989; 71-A:311.
    25. Golden WE, Lavender RC. Perioperative cardiac consultations in a teaching hospital. Southern Medical Journal. 1989; 82:292-295.
    26. Lavender RC, Golden WE, Barnes CL. Dihydroergotamine/ heparin compared to dextran in prophylaxis of dep venous thrombosis in total joint arthroplasty patients. Clinical Research. 1989; 37:778A.
    27. Barnes RW, Nix ML, Barnes CL, Lavender RC, Golden WE, Harmon BH, Ferris EJ, Nelson CL. Perioperative asymptomatic venous thrombosis: role of duplex scaning versus venography. Journal of Vascular Surgery. 1989; 11:218-222.
    28. Golden WE, Lavender RC. Physician preferences for chemistry profile bundling. Am Fed Clin Res. 1987.
    29. Golden WE, Lavender RC. Cardiac risk in noncardiac geriatric surgery. Ann Int Med. 1986; 104:887.
    30. Golden WE, Lavender RC, Pappas AA. Financial unbundling lowers utilization of outpatient testing. Am Fed Clin Res. 1986.
    31. Golden WE, Lavender RC. Preoperative consults to cardiology: implication for a general medicine service. Am Fed Clin Res. 1985.
    Lavender's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (43) concept(s)
    _
    Co-Authors Expand Description
    See all (1) people
    _
    Similar People Expand Description
    See all (30) people
    _
    Same Department Expand Description
    Search Department